Table 2.

TEAEs considered related to onalespib (≥10% of total patients)

Regimen 1 (n, %)Regimen 2 (n, %)
Adverse event preferred termOverall total, N = 48220 mg/m2, n = 20260 mg/m2, n = 3120 mg/m2, n = 22160 mg/m2, n = 3
AllGrade 3, 4AllGrade 3, 4AllGrade 3, 4AllGrade 3, 4AllGrade 3, 4
Diarrhea45 (94)10 (21)19 (95)3 (15)2 (67)2 (67)21 (96)3 (14)3 (100)2 (67)
Fatigue30 (63)6 (13)15 (75)1 (5)0014 (64)5 (23)1 (33)0
Decreased appetite25 (52)010 (50)01 (33)011 (50)03 (100)0
Nausea24 (50)1 (2)9 (45)01 (33)013 (59)1 (5)1 (33)1 (4)
Vomiting15 (31)05 (25)00010 (46)000
Dry mouth10 (21)05 (25)0004 (18)01 (33)0
Dizziness8 (17)03 (15)0005 (23)000
Infusion site pain7 (15)04 (20)0002 (9)01 (33)0
Anemia7 (15)5 (10)3 (15)1 (5)004 (18)4 (18)00
Headache6 (13)03 (15)0003 (14)000
Weight decreased6 (13)02 (10)0003 (14)01 (33)0
Dysgeusia6 (13)03 (15)0003 (14)000
Dry eye5 (10)02 (10)0003 (14)000
Photopsia5 (10)1 (2)2 (10)0003 (14)1 (5)00
Insomnia5 (10)02 (10)0003 (14)000